IMW 2021 | FORTE: updates on carfilzomib combinations and auto-SCT
Elena Zamagni
• 10 Sep 2021
Elena Zamagni, MD, PhD, University of Bologna, Bologna, Italy, shares an update on the Phase II FORTE trial (NCT02203643), which is investigating carfilzomib combined with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone, followed by autologous stem cell transplantation (auto-SCT) or 12 cycles of carfilzomib combined with dexamethasone and lenalidomide, for newly diagnosed multiple myeloma. Dr Zamagni reports that the trial demonstrated that the combination of proteasome and immunomodulatory drug is optimal, and that the addition of auto-SCT is particularly beneficial for high-risk patients. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.
